Engagements at Major Healthcare Conferences
Myriad Genetics, Inc. (NASDAQ: MYGN), a frontrunner in molecular diagnostic testing and precision medicine, is poised to participate in two pivotal healthcare conferences. Executives from Myriad will engage directly with investors, showcasing the company’s innovations and leadership in the field.
Upcoming Conference Details
On November 18, 2025, Myriad will take part in the 7th Annual Wolfe Research Healthcare Conference. This event will include a fireside chat, providing insights into the company's strategies and future directions.
In addition, Myriad will contribute to the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025. This session will also feature a fireside chat format, allowing for a more intimate exchange of information.
Access to Presentations
Investors interested in following these important discussions can access the live audio webcasts for both conferences. These will be made available on Myriad's investor relations website. Attending these conferences affords investors a unique opportunity to hear directly from Myriad’s leadership and understand their vision for the future of precision medicine.
About Myriad Genetics
Myriad Genetics is dedicated to enhancing health outcomes through innovative molecular diagnostic testing. The company’s tests are designed to assess the likelihood of disease development and progression, ultimately guiding treatment decisions. This personalized approach is critical across various medical specialties, where understanding molecular insights can significantly improve patient care and reduce healthcare costs.
By focusing on molecular diagnostics, Myriad helps facilitate more tailored medical solutions, ensuring that patients receive treatments tailored to their specific needs. This commitment to personalized medicine sets Myriad apart as a leader in the healthcare sector.
Contact Information
For more questions or to engage further, interested parties can reach out to Myriad’s Investor Contact, Matt Scalo, at (801) 584-3532 or via email at IR@myriad.com.
Media inquiries can be directed to Kate Schraml at (224) 875-4493 or through email at PR@myriad.com.
Frequently Asked Questions
What is the purpose of Myriad Genetics' participation in these conferences?
Myriad Genetics aims to engage with investors and share insights about their advancements in molecular diagnostic testing and precision medicine during these conferences.
How can I access the live presentations from the conferences?
The live audio presentations will be accessible through the investor section of Myriad Genetics’ official website during the respective conference dates.
What makes Myriad Genetics a leader in its field?
Myriad Genetics is recognized as a leader due to its innovative molecular tests that not only assess disease risks but also guide treatment decisions, improving patient care.
How does Myriad Genetics contribute to patient care?
By providing molecular diagnostics, Myriad helps healthcare professionals tailor treatments to individual patients, leading to better health outcomes and potentially lower healthcare costs.
Who should be contacted for further information about Myriad Genetics?
For further information, investors and media can contact Matt Scalo or Kate Schraml, respectively, through the provided contact details.
